AC 261066是视黄酸受体亚型β同工型2（RARβ2）的激动剂[1][2]。该物质也称作UVI2062[3]。AC 261066在大鼠中具有良好的口服生物利用度（Foral= 52%）[4]。AC 261066对AKR1B10的IC50值为51 ± 7 μM。在酶促试验中，AC 261066高达100 μM时对AKR1B1无抑制能力[3]。

视黄酸受体（RARs，亚型α、β、γ）与维甲酸X受体（RXR α、β、γ）形成二聚体复合物，编排复杂事件，如器官稳态、免疫功能、发育和繁殖[1]。RARβ2是视黄酸受体β亚型的同工体，其对视黄酸的亲和性和生物学功能与其他同工体不同[2]。

AC 261066不可诱导RPMI 8866 B细胞对ADAM28解聚素样结构域的细胞粘附，不可阻断atRA诱导的粘附[5]。

AC 261066治疗相比DMSO对照可显著抑制N. viridescens的尾部再生过程。当这些AC 261066处理的蝾螈在21天（分析时间）移除AC 261066，放回正常养殖水体，尾部再生开始。移除AC 26l066后五周，尾部完成再生。相比正常尾部再生，背腹图案发生了改变[6]。

参考文献：
[1].  Albane le Maire, Susana lvarez, Pattabhiraman Shankaranarayanan, et al. Retinoid Receptors and Therapeutic Applications of RAR/RXR Modulators. Current Topics in Medicinal Chemistry, 2012, 12: 505-527.
[2].  Christopher R. Gardner, Belamy B. Cheung, Jessica Koach, et al. Synthesis of retinoid enhancers based on 2-aminobenzothiazoles for anti-cancer therapy. Bioorg. Med. Chem., 2012, 20: 6877-6884.
[3].  Sergio Porté, Joan Giménez, Marta Dominguez, et al. Aldo–keto reductases in retinoid metabolism: Search for substrate specificity and inhibitor selectivity. Chemico-Biological Interactions, 2013, 202(1-3):186-94.
[4].  Birgitte W. Lund, Fabrice Piu, Natalie K. Gauthier, et al. Discovery of a Potent, Orally Available, and Isoform-Selective Retinoic Acid β2 Receptor Agonist. J. Med. Chem., 2005, 48: 7517-7519.
[5].  Jarrett T. Whelan, Lei Wang, Jianming Chen, et al. Retinoids induce integrin-independent lymphocyte adhesion through RAR-α nuclear receptor activity. Biochemical and Biophysical Research Communications, 2014, 454: 537-542.
[6].  Christopher J. Carter. Identification of novel retinoid receptors and their roles in vertebrate and invertebrate nervous systems [D]. St. Catharines: Brock University, 2011.